← back

Untitled

The computers still have to behave.

SOFIE’s network adds physical capacity, geographic coverage, and a useful answer to the old radiopharma problem of getting product to patients before the clock becomes the quality department. It also adds a large surface across which identity, batch records, release decisions, equipment telemetry, maintenance history, deviation evidence, and shipping data must remain aligned. A cyclotron can produce the isotope. It cannot establish, by itself, who approved the batch, which configuration ran the process, or whether the record arriving from another site deserves confidence.

Rockwell’s recent life sciences research puts the wider burden in blunt terms. Fifty four percent of life sciences manufacturers reported a cyberattack in the past year, with exposure concentrated around enterprise IT, remote access and connected equipment, and points where IT and operational technology meet. Those categories describe the ordinary machinery of a connected plant. They also describe the places where a radiopharmaceutical handoff can quietly acquire doubt.

I have watched perfectly good clinical work drown in spreadsheet handoffs. The spreadsheet was rarely the villain. It was the exhausted bridge between systems that had been purchased, validated, secured, and managed as separate institutional territories. The same arrangement becomes more unforgiving when a batch moves between sites, a release relies on records from several systems, and the product has a delivery window measured in hours.

A remote service account with excessive access can change the risk around a piece of equipment without touching the equipment itself. An ungoverned interface can move a status into a release workflow while leaving the provenance of the status unclear. A telemetry stream can be available for operations yet absent from the evidence package that quality teams must reconstruct after a deviation. Everyone can be following procedure while the system still produces an answer that nobody can defend.

That is why the acquisition and the cyber findings belong in the same Monday brief. GE HealthCare is acquiring manufacturing scale faster than the evidence chain naturally becomes coherent. The integration work will have to join site identity models, role boundaries, batch and release data, equipment records, audit trails, and validated interfaces without turning every local process into a central punishment exercise.

Teams stall here for understandable reasons. A common identity service threatens local habits. A shared data model exposes differences that local systems had politely concealed. Connecting plant equipment to enterprise services creates operational value and a new security boundary at the same time. Validation asks whether the intended process works. Security asks who can alter it. Quality asks whether the resulting record can survive inspection. These questions arrive in the same room and rarely agree on the calendar.

Meanwhile, the product keeps decaying.

The cleanest architecture diagram will not help if a release decision depends on a timestamp that means one thing at Site A and another at Site B. A well secured network still leaves trouble when an operator cannot see whether a failed handoff reflects a rejected batch, a delayed interface, or a missing acknowledgment. Usable controls matter because people under delivery pressure route around controls they cannot interpret. The workaround eventually becomes part of the process, usually without earning a change control number.

I want the engineers and the CMC leaders to argue over one sentence this week: can manufacturing scale be acquired faster than its evidence chain can be made trustworthy?

I refuse to answer that for you. The answer will sit in the identity provider, the manufacturing execution system, the laboratory record, the equipment gateway, the release workflow, and the audit trail that joins them. It will sit in the small decisions about whether a handoff is visible, whether an exception has an owner, and whether a receiving site can verify what the sending site claims before the isotope loses its usefulness.

Institutional theatre will offer a familiar response. There will be steering groups, integration milestones, and a confident diagram with arrows crossing between boxes. The receiving site will still need to know which batch it has, who released it, which instrument produced the critical data, and whether the evidence arrived intact.

That is the work. It is less glamorous than buying the network, more consequential than announcing it, and much harder to disguise with a presentation.

If this handoff problem is sitting inside your systems, hello@example.com is a sensible place to put the first uncomfortable question.' tags: - monday-brief - semantic-data - pharma title: 'Monday Brief: The Evidence Chain Has to Cross the Cyclotron' type: monday_brief

Related

The Plumbing That Decides Whether a Lab ScalesWhen a validated workload crosses cloud boundaries, the audit trail starts sweatingThe Fight for Identity in Pharma Data